Millions of American women are navigating a challenging landscape in their quest for estrogen patches, a vital component of hormone replacement therapy (HRT) for perimenopause and menopause symptoms. A widespread shortage, intensified by increased demand after the FDA removed black box labeling from estrogen-based HRT in November, has left many scrambling to find their prescriptions.
The situation has been described as a "high-stakes scavenger hunt," with women reporting significant difficulties in locating their medication. Elizabeth Borsting, who relies on HRT, found her local pharmacy out of stock and had to have a prescription filled 40 miles away. The urgency stemmed from her need to manage mood swings and other symptoms associated with fluctuating hormone levels.
Perimenopause, the transition to menopause, involves a gradual decrease in estrogen and progesterone production, leading to symptoms such as hot flashes, night sweats, brain fog, mood swings, and sleep disturbances. HRT aims to alleviate these symptoms by replenishing declining hormones. The FDA's decision in November to remove the black box warning, which had cautioned about potential increased risks of cardiovascular disease, dementia, and certain cancers, led to an anticipated rise in HRT use. However, this surge in demand quickly outstripped supply, creating a shortage that experts predict could last for several months to years.
Women are resorting to creative and often arduous measures to secure their HRT. Social media platforms have become hubs for sharing workarounds, including trading unused prescriptions and rationing patches by extending their use, though this carries risks of skin irritation. Some individuals have traveled significant distances, with one woman reporting her husband picking up her prescription nearly 400 miles away. Others are considering international trips, with mentions of traveling to Tijuana, Mexico, to obtain the medication.
Amy Roberts, a professional from Utah, has made multiple 45-minute drives to Salt Lake City to obtain her estrogen patches. Before HRT, she experienced severe insomnia, memory issues, and cognitive difficulties that impacted her daily life. The cost of these trips, including gas and lost time, adds to the burden.
Beyond the difficulty in obtaining patches, some women are exploring alternative therapies. Roberts and her friends are considering injectable peptides, such as NAD+ for brain fog and immunity, and GHK-Cu for skin and hair concerns. These treatments can be costly, with monthly expenses reaching hundreds of dollars out-of-pocket. However, medical professionals caution against these unapproved peptide treatments, stating they are not FDA-approved, not rigorously tested, and do not effectively manage key menopausal symptoms.
Laura Bray, founder of Angels for Change, an organization focused on drug shortages, noted that the pharmaceutical production cycle for generic drugs typically takes 12 to 18 months. The removal of the FDA's black box warning was not preceded by ample communication to manufacturers, contributing to the unexpected demand spike. The economic realities of pharmaceutical manufacturing also mean that less expensive generic drugs are more susceptible to shortages.
While doctors and pharmacists are recommending alternative forms of estrogen therapy, such as pills, gels, or mists, some patch users maintain these are not adequate substitutes for the convenience and perceived efficacy of the patches. The ongoing shortage raises concerns about potential health risks for women who cannot access consistent hormone therapy, especially given the known effects of estrogen decline on vascular health and cholesterol levels.